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Abstract The impact of direct oral anticoagulants (DOACs) on laboratory assays used for thrombo-
philia testing (e.g., antithrombin, protein S, protein C, lupus anticoagulant and activated
protein-C resistance) is a well-known issue and may cause false-positive and -negative
results. Therefore, the correct interpretation of tests that are performed in patients taking
DOACs is mandatory to prevent misclassification and the subsequent clinical conse-
quences. We aimed at evaluating the efficiency of a new and simple procedure (DOAC-
Stop®; Haematex Research, Hornsby, Australia) to overcome the effect of all DOACs in real-
life settings and toassess thepercentageoferroneous results dueto thepresenceofDOACs
on thrombophilia screening tests. For this purpose, 135 DOAC-treated patients (38
apixaban, 40 dabigatran, 15 edoxaban, and 42 rivaroxaban) and 20 control patients
were enrolled. A significant drop in apixaban, dabigatran, edoxaban, and rivaroxaban
plasma concentrations following the DOAC-Stop® treatment was observed (74.8–
8.2 ng/mL [p < 0.0001], 95.9–4.7 ng/mL [p < 0.0001], 102.1–8.8 ng/mL [p ¼ 0.001],
and 111.3–7.0 ng/mL [p < 0.0001], respectively). The DOAC-Stop® treatment was mostly
effective to overcome the effect of DOACs on PTT-LA, dilute Russell’s viper venom time
(dRVVT) screen, and dRVVT confirm tests. Using our procedures, false-positive results due
to DOACs were observed only with lupus anticoagulant tests (up to 75%) and fell to zero
after the DOAC-Stop® procedure, regardless of the DOAC considered. In conclusion, the
DOAC-Stop® adsorbent procedure appeared to be an effective and simpleway to overcome
the interference of DOAC on coagulation tests and should facilitate the interpretation of
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Direct oral anticoagulants (DOACs) including apixaban, dabi-
gatran etexilate, edoxaban, and rivaroxaban are used world-
wide since their approval in several thromboembolic
disorders, including the treatment and secondary prevention
of recurrent venous thromboembolism (VTE) and pulmon-
ary embolism (PE) as well as the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibril-
lation (NVAF).1–4
The impact of DOACs on laboratory assays used for
thrombophilia testing (e.g., antithrombin, protein S, protein
C, lupus anticoagulant, and activated protein-C resistance
[APC-R]) is a well-known issue and may cause false-positive
and -negative results.5–9 Therefore, the correct interpreta-
tion of results that are performed in patient taking DOACs is
mandatory to prevent misclassification and the subsequent
clinical consequences.7
Several strategies were proposed to minimize the impact
of residual DOACs on coagulation assays: (1) the use of DOAC-
insensitive assays, (2) the addition of idarucizumab to the
plasma sample (Praxbind, Boehringer Ingelheim) to specifi-
cally neutralize the in vitro activity of dabigatran,10 or (3)
missing one (for once-daily fixed-dose regimens) or two (for
twice-daily fixed-dose regimens) DOAC intake in patients
with low thromboembolic risk.6 However, any interruption
of anticoagulationwill expose the patient to an increased risk
of thrombosis and residual drug levels may still affect test
results.7 Thus, none of these approaches are considered
optimal and a simple way to overcome the problem would
be to remove DOAC from the plasma sample without influ-
encing its coagulant property.
The aim of this study was to evaluate the efficiency of a
new and simple procedure (DOAC-Stop®; Haematex
Research, Hornsby, Australia)11 to overcome the effect of
all DOACs in real-life settings and to assess the percentage of




The study protocolwas in accordancewith the Declaration of
Helsinki andwas approved by theMedical Ethical Committee
of the CHU UCL Namur, Université Catholique de Louvain
(Yvoir, Belgium, approval number 31/2016). Plasma samples
from135DOAC-treated patients (38 apixaban, 40 dabigatran,
15 edoxaban, and 42 rivaroxaban) and from 20 patients
without any anticoagulant (controls) were collected
between August 2014 and January 2018. The study popula-
tion displayed the following characteristics: 73 females and
82males aged 20 to 92 years (mean age ¼ 70 years). None of
these patientswere known to be LA positive. Bloodwas taken
by venipuncture in the antecubital vein and collected into
0.109 M sodium citrate (9:1 v/v) tubes (Vacuette, Greiner
Bio-One, Courtaboeuf, France) using a 21-gauge needle
(Greiner Bio-One). Platelet-poor plasma (PPP) was obtained
from the supernatant fraction of the blood tubes after a
double centrifugation for 15 minutes at 2,000 g at room
temperature. Immediately after centrifugation, PPP from the
155 patients were frozen at–80°C. Samples were thawed and
heated to 37°C for 5 minutes just before experiment.
Thrombophilia Testing
Protein S (antigenic assay, STA-Liatest Free Protein S; Diag-
nostica Stago, Asnières, France), protein C (chromogenic
assay, STA-Stachrom Protein C, Diagnostica Stago), antith-
rombin activity (thrombin based-assay, STA-Stachrom AT III,
Diagnostica Stago), and APC-R (Pefakit APC-R factor V Leiden
using factor V–deficient plasma; DSM, Basel, Switzerland)
were assayed on a STA-R MAX analyzer (Diagnostica Stago).
The dilute Russell’s viper venom time (dRVVT) screen and
confirm (STA-Staclot dRVV Screen and Confirm, Diagnostica
Stago) and the aPTT sensitive to lupus anticoagulants (PTT-
LA, Diagnostica Stago) were assayed on the KC10 coagul-
ometer (Amelung GmbH, Lemgo, Germany). LA was defined
as (1) a prolongation of screening tests (low phospholipid
[PL] concentration; dRVVT and/or PTT-LA), (2) a partial or no
correction of the prolonged clotting time after mixing
patient’s plasmawith normal pool plasma, and (3) a decrease
in the prolonged clotting timewith a confirmatory test (high
PL concentration).12,13 A dRVVT screen/dRVVT confirm ratio
was also calculated. The following cutoff valueswere used for
LA screening: PTT-LA ¼ 41 seconds (s); dRVVT screen ¼ 44
seconds; and [dRVVT screen/dRVVT confirm ratio] ¼ 1.2.
Normal ranges for protein S, protein C, antithrombin activity,
and APC-R were 50 to 134% for women and 70 to 148% for
men, 70 to 120%, 80 to 120%, and >2, respectively.14,15
Direct Oral Anticoagulant Measurement
Concentrations of dabigatran were estimated using one
Ecarin chromogenic assay (STA-ECA-II, Diagnostica Stago),
and concentrations of apixaban, edoxaban, and rivaroxaban
with the corresponding procedure using the chromogenic
assay (STA-liquid anti-Xa, Diagnostica Stago). All these pro-
cedures were performed on the STA-R MAX analyzer (Diag-
nostica Stago). The limit of quantification of the
corresponding apixaban, dabigatran, edoxaban, and rivarox-
aban assays were 15, 27, 20, and 25 ng/mL, respectively.16–19
DOAC-Stop® Treatment
Thrombophilia screening tests were performed before and
after the addition of adsorbent tablets (DOAC-Stop®; Haema-
tex Research, Hornsby, Australia), according to the manufac-
turer’s instructions and depending on the available plasma
volume.11Briefly, one tablet ofDOAC-Stop®designed to adsorb
DOACs is added to 1 mL of plasma. Thereafter, the sample is
gentlymixed for5minutes andspunfor2minutes at 2,000 g to
precipitate DOACs with these adsorbent tablets. Finally, the
supernatant supposed to be free fromDOACs is collected to be
further analyzed. The composition ofDOAC-Stop® isHaematex
proprietary information. Concentrations of apixaban, dabiga-
tran, edoxaban, and rivaroxabanwere also assayed before and
after theDOAC-Stop®procedure. TheDOAC-Stop® treatment in
plasma samples without DOAC or anti-Xa activity was found
to minimally affect the aPTT and PT. 11,20
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Statistical Analysis
False-positive LA results caused by DOACs were compared
with the results obtained after the DOAC-Stop® treatment. A
paired t-test was used in case of passed normality test and a
Wilcoxon matched-pairs signed rank test in case of failed
normality test (D’Agostino–Pearson normality test). A
p-value <0.05 was considered as statistically significant.
The concept of reference change value (RCV) used to detect
minimal difference between two measurements was also
employed to assess significant clinical changes after the
DOAC-Stop® treatment. The RCV combined the analytical
imprecision (CVA) and the intraindividual coefficient of
variation (CVI) andwas calculated by the following equation:
[RCV ¼ 21/2  Z (1.96 for a probability of 95%)  (CVA2 þ
CVI2)1/2].21 Biological variation data (CVI) were found in the
literature.22,23 GraphPad Prism 6.0e (California, United
States) was used to perform statistical analysis.
Results
Plasma concentrations of apixaban, dabigatran, edoxaban,
and rivaroxaban before DOAC-Stop® treatment varied from
10 to 316 ng/mL, 2 to 406 ng/mL, 21 to 354 ng/mL, and 7 to
456 ng/mL, respectively. A significant drop in apixaban,
dabigatran, edoxaban, and rivaroxaban concentrations fol-
lowing the DOAC-Stop® treatment was also observed (from
74.8 to 8.2 ng/mL [p < 0.0001], from 95.9 to 4.7 ng/mL
[p < 0.0001], from 102.1 to 8.8 ng/mL [p ¼ 0.001], and
from 111.3 to 7.0 ng/mL [p < 0.0001], respectively;
►Fig. 1). The residual level of each DOAC was lower than
the limit of quantification of the corresponding apixaban,
dabigatran, edoxaban, and rivaroxaban assays.16–19
The DOAC-Stop® treatment was mostly effective to over-
come the effect of DOACs on PTT-LA, dRVVT screen, and
dRVVT confirm tests (►Table 1 and ►Fig. 2). False-positive
results were observed only with LA tests (up to 75%) and fell
to zero after the DOAC-Stop® procedure, regardless of the
DOAC considered (►Table 2).
Significant differences following the DOAC-Stop® proce-
dure were also observed for the protein S (dabigatran,
p ¼ 0.005) and antithrombin activity (apixaban and edox-
aban, p ¼ 0.03 and p ¼ 0.01). However, differences obtained
before and after the DOAC-Stop® treatment were always
below the RCV, whatever the DOAC tested. The clinical
impact is therefore not relevant (►Fig. 2).
Except for rivaroxaban (p ¼ 0.98), a significant difference
was observed for APC-R. The most obvious difference was
pointed out in the dabigatran group (mean absolute differ-
ence of 2.0).
No significant changeswere observed in the control group.
Discussion
Our observations confirmed that APC-R, PTT-LA, dRVVT
screen, dRVVT confirm, and dRVVT ratio could be influenced
by DOACs and that false-positive LA results were encoun-
tered with all DOACs.5–7,24 The DOAC-Stop® treatment
appeared to be an effective way to overcome the effect of
DOACs on these aforementioned tests. Furthermore, the
DOAC-Stop® procedure did not significantly affect all throm-
bophilia screening tests in control patients.
The impact of DOACs on these tests is a well-known issue,
but the concentrations at which thrombophilia assays are
impacted are not well defined yet and few data are available
for edoxaban. Nevertheless, it is not recommended to per-
form LA testing in patients taking DOACs, as these may cause
false-positive results in a concentration-dependent man-
ner.8,25 It is recommended to stop taking DOACs at the
time of thrombophilia testing (for at least 2 days or at trough
concentration) to overcome the interference.6,7,25,26 How-
ever, the discontinuation of the treatment is not clinically
recommended7 and a high variability of DOACs trough levels
has been reported.27Moreover, patients may also choose not
to stop their DOAC treatment (or forget to stop) before
thrombophilia testing, which could lead to wrong diagnosis
and clinical consequences.7,9 Some authors recommended to
detect LA using taipan snake venom time (TSVT), Ecarin
clotting time (ECT), or textarin clotting time (TCT) as they are
not affected by anti-Xa drugs.7,25,28–30 However, these alter-
natives are not readily available in clinical practice6,7 and are
only appropriate for anti-Xa drugs, thus requiring different
procedures depending on the drug.
Our results showed that DOACs had a higher impact on the
dRVVT screen assay compared with PTT-LA and dRVVT ratio.
First, false-positive results were already encountered at
concentration as lowas 20, 23, 21, and 54 ng/mL of apixaban,
dabigatran, edoxaban, and rivaroxaban, respectively. Second,
the mean relative decrease following the DOAC-Stop® treat-
ment was higher for dRVVT screen (26.8, 47.5, 36.4, and
46.9% for apixaban, dabigatran, edoxaban, and rivaroxaban,
Fig. 1 Impact of the DOAC-Stop® adsorbent treatment on apixaban, dabigatran, edoxaban, and rivaroxaban concentrations. The mean (and 95%
confidence interval) of each direct oral anticoagulant is presented before and after the DOAC-Stop® treatment.
TH Open Vol. 2 No. 2/2018
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respectively) compared with PTT-LA (11.0, 32.2, 10.2, and
16.6%) and dRVVT confirm (26.3, 38.1, 29.7, and 29.6%;
►Tables 1 and 2).
Third, the number of false-positive values was higher for
dRVVT screen compared with PTT-LA and dRVVT ratio
whatever the DOAC considered (►Table 2). These observa-
tions are consistent with recent publications showing that
the dRVVTscreen is themost sensitive test to the presence of
DOACs.24,25 False-positive results for all LA tests (PTT-LA,
dRVVT screen, dRVVT confirm, and dRVVT ratio) were
encountered regardless of the DOAC considered. Except for
rivaroxaban, differences between dRVVT ratio values before
and after the DOAC-Stop® treatment (dRVVT screen/dRVVT
confirm) were all included in the RCV interval found in the
literature. This must be explained by the fact that both
dRVVT screen and dRVVT confirm are influenced by DOAC’s
presence in a proportional way. Therefore, a normal dRVVT
ratio does not exclude the interference of DOAC.
Proteins S and C may be measured by three different
methods: clot-based, antigenic, or chromogenic. Only clot-
Fig. 2 Impact of the DOAC-Stop® adsorbent treatment on common thrombophilia screening tests. The gray zone corresponds to the reference
change value interval of each test. The mean (and 95% confidence interval) of each parameter is presented before and after the DOAC-Stop®
treatment.
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based methods would be affected by DOACs.5,6,8,24 As we
have used an antigenic assay for protein S and a chromogenic
assay for protein C, it explains that the results were not
overestimated before the DOAC-Stop® treatment. It is also
reassuring to note the absence of significant difference after
the DOAC-Stop® procedure when applied on the controls
which suggests that this product could be used without
affecting both proteins S and C. This information is useful
for practical reasons, as we showed that the DOAC-Stop®
treatment does not require slitting the sample into two
aliquots (one treated and the other not treated by DOAC-
Stop®).
The APC-Rmethods based on the aPTT and using factor V–
deficient plasma are mostly affected by all DOACs.5,6,24,31
However, it is known that rivaroxaban does not interfere
with the Pefakit APC-R factor V Leiden (prothrombinase-
based assay) used in this study,6,32,33 while the dabigatran
and edoxaban do.8,34,35 Accordingly, we found a significant
decrease following the DOAC-Stop® procedure for dabigatran
(ratio from 6.6 to 4.6, p < 0.0001) and to a lesser extent for
edoxaban (ratio from 4.5 to 4.2, p ¼ 0.001). No significant
decrease was found for rivaroxaban (►Table 1 and ►Fig. 2).
Interestingly, theDOAC-Stop® treatment did not decrease the
APC-R of patients taking apixaban.
The antithrombin activity is not affected by the presence
of direct Xa inhibitors (apixaban, edoxaban, and rivaroxaban)
when measured with a thrombin-based assay.5–7,36 As
observed for protein S and C, the DOAC-Stop® procedure
did not significantly affect the antithrombin activity given
that we used a thrombin-based assay.5–7,36 Although we
used a thrombin-based antithrombin assay, no significant
difference for dabigatran following the DOAC-Stop® treat-
ment was observed. According to the in vitro study of
Douxfils et al, dabigatran started to interfere with antith-
rombin at higher concentration (>100 ng/mL) in a thrombin-
based assay.37 The median concentration of our patient
samples for dabigatran was quite low (73.5 ng/mL) and
may therefore explain the absence of significant difference
after the DOAC-Stop® procedure.
Thus, compared with the use of idarucizumab (Praxbind,
Boehringer Ingelheim) to overcome the in vitro effect of
dabigatran or the use of other alternatives for LA screening
tests (e.g., TSVT, ECT, or TCT), the DOAC-Stop® procedure has
the advantage to remove all types of DOACs, to be simple,
cheap, and easily accessible.
Our study has some limitations. Our population did not
contain factor V Leiden carriers, LA-positive patients, and
deficient in protein S and C. It would be useful to determine if
the DOAC-Stop® treatment may have an impact on these
particular patients. However, vitamin K antagonists are the
treatment of choice for antiphospholipid syndrome, protein
S or protein C deficiency, while DOAC’s use is still contro-
versial.38–41 Additional studies designed to evaluate the
efficiency of DOAC-Stop® treatment with a larger range of
DOAC’s concentration on more coagulation tests (including
clotting factors and instruments using optical clot detection)
will also be useful. Biological variation data (CVI) obtained
from the publication of de Maat et al were determined with
the same reagents and on a similar platform (STA Compact
analyzer, Diagnostica Stago).23However, the CVI provided by
Shou et al were obtainedwith different settings (ACLTOP 700
analyzer, Instrumentation Laboratory, Bedford, MA).22
Therefore, the RCV used in this study for LA tests may vary
for other platforms. Nevertheless, we did not show any false-
positive PTT-LA, dRVVT screen, and dRVVT confirm results
following the DOAC-Stop® procedure. Information on biolo-
gical variation in hemostasis variables (e.g., APC-R, PTT-LA,
and dRVVT confirm) is still limited and need further evalua-
tions,23 but these results are clearly encouraging.
Conclusion
This real-life study confirms that thrombophilia assays are
frequently influenced by the presence of DOACs. The impor-
tance depends on the DOAC and on the assay considered.
Moreover, the DOAC-Stop® adsorbent procedure appeared to
be an effective and simple way to overcome the interference
of DOAC on coagulation tests. Our findings should facilitate
the interpretation of thrombophilia screening tests in
patients taking DOACs and we suggest the use of the
DOAC-Stop® treatment in clinical practice to avoid potential
misclassifications and clinical consequences.
Table 2 False-positive LA results caused by DOACs




































Abbreviation: dRVVT, dilute Russell’s viper venom time.
Notes: The following cutoffs were used to calculate the number of false-positives values: PTT-LA ¼ 41 seconds; dRVVT screen ¼ 44 seconds; and
[dRVVT screen/dRVVT confirm ratio] ¼ 1.2.
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